On 22 October 2007, orphan designation (EU/3/07/455) was granted by the European Commission to Novagali Pharma SA, France, for ciclosporin for the prevention of corneal graft rejection.
In March 2015, Novagali Pharma SA changed name to SANTEN SAS.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
Prevention of corneal graft rejection
|Orphan designation status||
|EU designation number||
|Date of designation||
Bâtiment Genavenir IV
1, Rue Pierre Fontaine
Tel. +33 1 69 87 40 20
Fax +33 1 69 87 40 30
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: